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Abstract: Vitamin B6 is a cofactor for approximately 150 reactions that regulate the metabolism
of glucose, lipids, amino acids, DNA, and neurotransmitters. In addition, it plays the role of
antioxidant by counteracting the formation of reactive oxygen species (ROS) and advanced glycation
end-products (AGEs). Epidemiological and experimental studies indicated an evident inverse
association between vitamin B6 levels and diabetes, as well as a clear protective effect of vitamin B6
on diabetic complications. Interestingly, by exploring the mechanisms that govern the relationship
between this vitamin and diabetes, vitamin B6 can be considered both a cause and effect of diabetes.
This review aims to report the main evidence concerning the role of vitamin B6 in diabetes and to
examine the underlying molecular and cellular mechanisms. In addition, the relationship between
vitamin B6, genome integrity, and diabetes is examined. The protective role of this vitamin against
diabetes and cancer is discussed.
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1. Vitamin B6: Roles and Synthesis
Vitamin B6 is a very important compound for general cellular metabolism [1]. The term vitamin
B6 refers to six common forms or vitamers, namely pyridoxine (PN), pyridoxal (PL), pyridoxamine
(PM), and their related 5′-phosphate derivatives (PNP, PLP, and PMP). The biologically active form,
the pyridoxal 5′-phosphate (PLP), acts as coenzyme in about 150 distinct enzymatic activities that
catalyze crucial metabolic reactions, such as synthesis, transformation, and degradation of amines
and amino acids, supply of one carbon units, transsulfuration, synthesis of tetrapyrrolic compounds
(including heme) and polyamines, biosynthesis, and degradation of neurotransmitters [2,3]. Although
vitamin B6 is not classified as a classical antioxidant compound, it is able to quench oxygen reactive
species (ROS) [4] and counteract the formation of advanced glycation end products (AGEs), genotoxic
compounds associated with senescence, and diabetes [5]. Furthermore, PLP works as a modulator of
transcription factors, has a role in enzyme folding, and can bind to steroid receptors, playing a role in
membrane transport [6].
Mammals, different from microorganisms, are not able to synthesize PLP but recycle it through
a salvage pathway from B6 vitamers as pyridoxal (PL), pyridoxamine (PM), and pyridoxine (PN)
contained in food [7]. In the cytoplasm PL, PM, and PN are converted into the 5′-phosphorylated
vitamers through pyridoxal kinase (PDXK), while the FMN-dependent pyridoxine 5′-phosphate
oxidase (PNPO) converts PNP and PMP into PLP (Figure 1). Once ingested, PLP, PNP, and PMP
are dephosphorylated by the tissue-non-specific alkaline phosphatase (TNSALP), which is anchored
to the cell membrane. Then, PM, PN, and PL are absorbed from the upper small intestine by
a carrier-mediated system and is delivered to the liver. Here, they are converted to PLP, thanks
to the combined action of PDXK and PNPO. From the liver, PLP bound to albumin, along with
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dephosphorylated B6 vitamers, reach the peripheral tissues through the blood stream. In order to
enter cells, PLP needs to be dephosphorylated again by TNSALP [8]. In the cytosol, a ubiquitous PLP
phosphatase is instead required for vitamin B6 catabolism [9].
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Vitamin B6 recommended dietary allowance is 1.3 mg day-1 for adults; it is present in several
foods including meat, fish, poultry, vegetables, and fruits, thus, a severe deficiency of this vitamin is
uncommon in developed countries, within any diet. However, PLP concentrations appear to be reduced
in certain contexts, as for example, alcoholism [10], obesity [11], and pregnancy [12]. Moreover, some
pathological conditions such as end-stage renal diseases, chronic renal insufficiency, and other kidney
diseases can lower the vitamin B6 levels [12]. In addition, vitamin B6 deficiency has been correlated
to malabsorption syndromes, such as celiac disease and inflammatory bowel diseases [12–14]. Even
the intake of certain medications, including isoniazid [15], penicillamine [16], and cycloserine [17],
as well as oral contraceptives, can reduce PLP availability [18]. PLP levels can also be decreased by
the inflammation conditions and stress hormones [19,20].
2. Vitamin B6 and Diabetes
By onsidering the plethora of reactions in which vitamin B6 is involved, it is n t surprising that its
deficiency has been implicated in several clinically relevant diseases, including autism, schizophrenia,
Alzheimer, Parkinson, epilepsy, Down’s syndrome, diabetes, and cancer; however, the underlying
mechanisms remain unknown in most cases [21–23].
Diabetes mellitus (DM) represents a global health problem, touching more than 400 million
people and consists of a group of metabolic disorders characterized by persistent hyperglycemia
arising from impaired insulin secretion, insulin action, or both [24]. DM is a multifactorial disease
caused by the concerted action of genetic and environmental factors, and on the basis of its etiology, it
can be classified into three major types—type1 (T1D), type2 (T2D), and gestational diabetes (GDM).
T1D is an autoimmune disorder that leads to the destruction of pancreatic beta-cells and accounts
for only 5–10% of all diabetes. T2D, the more frequent form (90–95%), is mainly caused by insulin
Int. J. Mol. Sci. 2020, 21, 3669 3 of 18
resistance consisting of a diminished tissue response to insulin that leads glucose to accumulate in
blood. Consequently, the rate of insulin secretion increases to meet the body’s needs, but this overload,
in the long-term, compromises pancreas functionality. GDM is a common pregnancy complication that
affects approximately 14% of pregnancies worldwide. It is associated with insulin resistance, in turn
generated by a combined action of pregnancy hormones and other factors [25].
Substantial evidence correlates vitamin B6 to diabetes and its complications. Some population
screenings have been carried out to compare PLP levels in diabetic groups vs. healthy subjects; in
addition, several studies focused on the impact of vitamin B6 on diabetic complications and others on
the effectiveness of vitamin B6 as a preventive treatment. Vitamin B6 levels are commonly assessed by
measuring plasma pyridoxal 5′-phosphate (PLP) concentration and an inadequate vitamin B6 status
is generally associated with a concentration, under the cut-off level of 30 nmol/L. Other methods
include the measurement of plasma pyridoxal or total vitamin B6 and urinary 4-pyridoxic acid, as well
the ratio between PLP and PL [26]. By examining the studies reported in literature, an inverse relation
between vitamin B6 levels and diabetes emerges. Satyanarayana and coworkers [27] in a cross-sectional
case-control study found that the mean plasma PLP levels were significantly lower in T2D subjects,
compared to the healthy controls. By comparing the results obtained in a Korean study by Ahn
and coworkers [28] to those obtained by Nix and collaborators [29] in a German cohort, vitamin B6
levels appeared to be inversely related to the progression of diabetes. Ahn and collaborators [28],
in fact, examined diabetic people with an early status of the disease, finding a mean plasma PLP
level reduction to be relevant but not statistically significant, with respect to controls; in contrasts,
the diabetic group examined by Nix [29], being composed of people with advanced clinical stage,
exhibited median plasma concentrations of PLP, PN, and PL that were significantly decreased in
a diabetic group compared to the controls. Interestingly, median plasma levels of the PM, PMP,
and pyridoxic acid were significantly higher in the diabetes groups than in the controls; this finding
led Nix and collaborators to advance the hypothesis that T2D might be associated with an altered
activity of the enzymes involved in the interconversion of B6 vitamers [29]. In another study, based on
the evidence of increased urinary clearance of vitamin B6, it was hypothesized that decreased vitamin
B6 levels in T2D subjects could derive from an impaired reabsorption processes [30]. The same inverse
relationship between B6 levels and diabetes was observed in experimental animals [31,32]. Roger was
the first to describe decreased PLP levels in streptozotocin-diabetic rats accompanied by less storage in
the liver of the mitochondrial PLP [31].
Decreased PLP levels have also be associated with GDM. In a study performed in a group of
women affected by GDM, Bennink and Schreurs [33] found that 13 out of 14 displayed reduced PLP
levels. Moreover, pyridoxine administration ameliorated oral glucose tolerance. Analogous results
were obtained by Spellacy and coworkers [34], which found a clear blood glucose decrease and
a normalization of insulin secretion following pyridoxine therapy in GDM women, indicating that
vitamin B6 might ameliorate plasma insulin biological activity.
Other intervention studies reported that pyridoxine supplementation is capable of lowering blood
glucose levels in streptozotocin-treated rats [35], as well as glycosylated hemoglobin levels in T2D
patients [36]. Moreover, Kim and collaborators [37] showed that vitamin B6 can reduce postprandial
blood glucose levels following sucrose and starch ingestion, by inhibiting the activity of small-intestinal
α-glucosidases.
3. Is Reduced Vitamin B6 Availability the Cause or the Effect of Diabetes?
Although an evident link exists between vitamin B6 and diabetes, it is not clear whether the diabetic
status is responsible for decreasing PLP availability or, in contrast, whether reduced PLP levels represent
a causative agent of diabetes. By examining the literature, it appears that both hypothesis might be
plausibly true, suggesting the existence of a vicious circle that correlates vitamin B6 and diabetes.
In this paragraph, we reported some evidence in support of each hypothesis by just mentioning
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some underlying mechanisms that were proposed. In Section 4, we examine in greater details,
the mechanisms through which more experimental data converge.
3.1. Diabetes Decreases Vitamin B6 Levels
The first evidence that diabetes can reduce PLP levels was provided by Leklem and Hollenbeck [38]
who demonstrated that the ingestion of glucose by healthy subjects caused a reduction of PLP levels.
In agreement with this idea, Okada and coworkers [32] proposed that diabetes might lead to vitamin
B6 deficiency as a result of an increased rate of protein metabolism, due to a diet low in carbohydrates
and rich in proteins. Since PLP is cofactor for many enzymes involved in protein metabolism, an
increased PLP demand would cause a decrease of PLP in other tissues. This hypothesis is based on
the finding that the amount of PLP was found increased in the liver of streptozotocin-diabetic rats,
with respect to the nondiabetic controls, but was reduced in the plasma, kidney, and muscles [32].
Accordingly, in diabetic rats fed a low PLP diet, the activity of aspartate amino transferase, an enzyme
that is PLP-dependent and is involved in the protein metabolism, was found to be four times greater
in the liver of diabetic, as compared to the non-diabetic controls. In contrast, the activity of another
PLP-dependent enzyme, the glycogen phosphorylase, was decreased in the muscles of diabetic rats
as compared to non-diabetic animals, although the regulation of this enzyme in the muscles also
depended on many other factors.
Epidemiological, clinical, and experimental studies have indicated an association between
low-grade inflammation and both T1D [39] and T2D [40,41]. Moreover, the role of inflammation in
the pathogenesis of T2D and vascular complications was confirmed by intervention studies [41]. In
diabetic patients, an inverse relationship between plasma PLP and inflammation markers was found [29].
Therefore, it was proposed that in diabetes, the decline in PLP levels might be due to (1) the mobilization
of this coenzyme to the site of inflammation; (2) increased demand by the PLP-dependent enzymes
involved into the tryptophan kynurenine pathway; and (3) immune cell proliferation [42]. However,
more research is needed to confirm these mechanisms.
3.2. Reduced Vitamin B6 Levels Trigger Diabetes
A cause–effect relation between low PLP levels and diabetes emerged from the work of Toyota
et al. [43], which showed that pyridoxine deficiency can impair insulin secretion in rats. In addition,
by performing in vitro experiments of pancreas perfusion, the authors also found that insulin and
glucagon secretion was impaired in the pyridoxine deficiency.
Low vitamin B6 levels are believed to cause GDM, based on the consideration that in pregnancy,
PLP levels tend to decline due to the movement of pyridoxine to fetus and, in addition, on the finding
that pyridoxine treatment ameliorates glucose tolerance in GDM women [34].
Reduced vitamin B6 availability might also contribute to the appearance of pancreatic islet
autoimmunity in T1D. This idea is based on the consideration that PLP is a cofactor for glutamic acid
decarboxylase (GAD-65), which represents an important autoantigen implicated in the pathogenesis of
T1D. It was hypothesized that reduced levels of the coenzyme might trigger autoimmunity by altering
stability, tridimensional conformation, or antigenicity of GAD65 [44].
The most direct evidence indicating that vitamin B6 deficiency could cause diabetes was provided
by data from studies in Drosophila, showing that mutations in genes involved in vitamin B6 metabolism
cause diabetes [45,46].
Mutations in Genes Involved in Vitamin B6 Synthesis Cause Diabetes
In pathophysiological studies, cause–effect relationships at the basis of a given disease can be
inferred by examining the effects of mutations in the involved genes. This approach is difficult to
pursue in human research but is widely used in model organisms. Drosophila melanogaster, a successful
organism for genetic and cytogenetic studies [47], in the last 10 years, turned out to be a powerful
resource to study metabolic diseases, given that the flies share 75% of genes with humans, as well as
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major metabolic pathways. Both T1D and T2D were modeled in flies and diabetic hallmarks, such as
hyperglycemia, altered lipid metabolism, reduced body dimensions, and obesity, were extensively
described [48–50].
Interestingly, in Drosophila, the impact of mutations on diabetes was analyzed in the genes
involved in the vitamin B6 salvage pathway, such as pyridoxal kinase (dPdxk) and pyridoxine 5′-phosphate
oxidase (sgll). These studies revealed that mutations in the dPdxk gene caused a significant increase
in the glucose content of the larval hemolymph (the human blood) [45]. Moreover, the finding
that insulin signaling is reduced in the dPdxk mutant larvae, suggested that dPdxk mutants might
represent a new model of T2D [45]. In agreement with these results, the silencing of sgll by RNA
interference produced diabetic hallmarks, such as hyperglycemia, reduced body size, and altered lipid
metabolism [46]. Moreover, vitamin B6 administration rescues diabetic phenotypes in both Pdxk and
Sgll depleted individuals, whereas the treatment with the PLP inhibitor 4-deoxypyridoxine (4-DP)
causes hyperglycemia in wild type individuals [45,46,51].
Studies aimed at correlating the expression of PDXK or PNPO human genes with diabetes are
still scarce, but encouraging. Moreno-Navarrete and coworkers [52] demonstrated that reduced
PDXK expression impacts the lipid metabolism (see Section 4.2), raising the possibility that vitamin
B6 in obesity can protect from insulin resistance. Moreover, our group also found a link between
human PDXK gene and diabetes. We demonstrated that the expression, in dPdxk1 mutant flies,
of 4 PDXK variants with impaired catalytic activity or affinity for substrates was unable to rescue
the hyperglycemia due to dPdxk1 mutation, from the wild-type PDXK protein [53].
4. Mechanisms Underlying the Link between Vitamin B6 Diabetes
By considering that PLP is involved in a plethora of metabolic reactions by working as a coenzyme,
as well as antioxidant molecule, it is plausible that reduced vitamin B6 levels can impact different
diabetic contexts, through different mechanisms. In the Section 3, some hypotheses concerning
the mechanisms that relate vitamin B6 to diabetes are mentioned. In this section, the pathways on
which most studies converge are analyzed in more detail.
4.1. Vitamin B6 and Tryptophan Metabolism
One way through which PLP impacts diabetes concerns the metabolism of tryptophan (TRP),
an essential amino acid, which is a substrate for the biosynthesis of menthoxyindoles, such as
serotonin, N-acetylserotonin, and melatonin. About 95% of TRP is metabolized through the kynurenine
(KYN) pathway to produce NAD [54] (Figure 2). TRP- or indoleamine-2,3-dioxygenases (TDO
or IDO) convert TRP to KYN and the activity of these enzymes is a rate-limiting step, increased
by stress hormones or inflammatory factors (e.g., IFNG and LPS) [55]. KYN is then converted in
3-hydroxykynurenine (3-HKYN), through the action of KYN-monooxygenase (KMO). KYN and
3-HKYN can be converted, respectively, in kynurenic acid (KYNA) and xanthurenic acid (XA), through
the activity of the aminotransferases (KAT), which is a PLP-dependent enzyme. The conversion of
3-HKYN into the 3-hydroxyanthranilic acid (3-HAA) is performed by kynureninase (KYNU), which
also depends on PLP for its activity. As KYNU is more sensitive to deficiency of PLP, with respect to
KAT [56], PLP deficiency diverts 3-HKYN metabolism from the formation of 3-HAA, to accumulation
of KYNA and XA [57–60].
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Evidence exists that the tryptophan metabolism is impaired in the different forms of diabetes, due
to many factors and conditions, such as pregnancy, oral contraceptives, and emotional and metabolic
stress hat reduce P P availability [33,61]. Accordingly, it was found that XA was excessively excreted
in diabetic patients [62,63]. Analogously, GDM women after an oral load of TRP exhibited increased
XA excretion reduced by PLP administration [33]. Similar results came from animal studies. It was
shown that streptozotocin-diabetic rats on TRP treatment excreted much more XA and other TRP
metabolites, compared to non-diabetic rats [64] and, more recently, metabolomic studies reported
increased KYNA levels in the urine of nonhuman primate and T2D mouse models [65]. Moreover,
evidence exists that the KYN pathway is activated in obesity [66] and XA levels have been found to be
elevated in pre-diabetic status [67], suggesting that the TRP pathway impairment might contribute to
insulin resistance, which precedes T2D [68].
Interestingly, XA has diabetogenic properties because its administration to rats induced diabetic
symptoms, worsened by B6 deficiency, including pathological modifications of the pancreatic beta cell
tissue [69]. It was proposed that the TRP metabolites impact diabetes through different mechanisms,
which can compromise either the insulin activity or insulin secretion. TRP metabolites can be
responsible for the (1) formation of chelate complexes with insulin (XA–In), which have about a 50%
lower activity compared to pure insulin [70]; (2) formation of Zn++ ion–insulin complexes in β cells
that cause a toxic effects on the isolated pancreatic islets [63,71]; (3) inhibition of insulin release from
the rat pancreas [72], and (4) induction of pathological apoptosis of pancreatic beta cells [73].
Altered TRP metabolisms is associated with diabetic complications. An elevation in
the concentrations of tryptophan metabolites and IDO expression was evident in diabetic retinopathy
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patients [74]. Moreover, a significant inverse association between toxic TRP metabolites and the stages
of chronic kidney diseases, which occur as diabetes complications, was reported [75].
4.2. Vitamin B6 and Lipid Metabolism
Reduced vitamin B6 availability can also impact insulin resistance through the lipid metabolism.
It was shown that in obese people, adipogenesis and lipotossicity can promote insulin resistance [76,77].
Contrary to previous knowledge that adipogenesis ceases early in the life with a fixed number of
adipocytes, the fat cells experience a dynamic process of turnover through which the adipocytes
differentiate from pre-adipocyte into mature adipocytes. During adipogenesis, a shift in the gene
expression replaces the transcripts proper of the adipocyte early stage with the transcripts responsible
for the final maturation [78]. It was shown that adipocyte maturation is compromised in T2D. Larger
adipocytes, but similar number of fat cells, were found in diabetic individuals compared to non-diabetic
people; moreover, insulin sensitivity was shown to be inversely related to fat cell size. Furthermore,
the expression level of some genes involved in adipogenesis was shown to be reduced in T2D subjects,
compared to obese non-diabetic individuals [79].
Vitamin B6 is involved in adipogenesis. First evidence come from works in rat models that
showed that a vitamin B6-deficient diet significantly reduced adipose tissue and lipogenesis [80–82].
Later, it was shown that vitamin B6 administration increased intracellular lipid accumulation in 3T3-L1
adipocytes [83], and reduced macrophage infiltration and adipose tissue inflammation in mice [84,85].
Furthermore, it was shown that vitamin B6 is present at low circulating concentrations in obese
people [86]. More recent research by Moreno-Navarrete and coworkers [52] provided more clues
on the role played by vitamin B6 in adipogenesis. The authors, by examining adipose tissues from
obese subjects, found lower PLP levels in visceral adipose tissues vs. subcutaneous ones; accordingly,
they found the PDXK expression levels to be significantly reduced and associated with that of
the adipogenic genes. In addition, they also demonstrated that PDXK mRNA levels, during adipocyte
differentiation, were reduced by inflammatory conditions. Moreover, the inhibition of the PDXK
activity (mediated by 4-DP) reduced adipogenic gene expression, during adipocyte differentiation,
whereas PLP administration produced the opposite effect [52].
How exactly PLP regulated adipogenes is not fully elucidated. It was proposed that PLP might
activate peroxisome proliferator-activated receptor-γ (PPARγ), one of the master nuclear receptor
involved in the expression of adipogenesis genes [83]. Alternatively, PLP might conjugate with RIP140,
a nuclear transcription factor, by enhancing its co-repressive activity and its physiological function in
adipocyte differentiation [87,88]. Moreover, based on the finding that an altered DNA methylation
is associated with adipose tissue dysfunction in T2D patients [89], given that PLP is a coenzyme
for serine hydrossymethiltranferase (SHMT), vitamin B6 might contribute to maintain the correct
methylation pattern.
Vitamin B6 might also impact the lipid metabolism, through different mechanisms. It was
proposed that reduced levels of vitamin B6 might increase levels of homocysteine, as PLP is a cofactor
for cystathionine-synthase (CBS) and cystathionine-lyase (CGL), which are involved in the metabolism
of this compound [90]. Elevated homocysteine levels are associated with obesity; in addition, they can
impair endothelial function and lead to lipid accumulation in liver [91–93].
The protective role of vitamin B6 against hepatic lipid accumulation is sustained by the evidence
that vitamin B6 administration reduced the accumulation of lipids in livers of high-fat diet-fed Apoe−/−
mice [90] and also that patients affected by nonalcoholic fatty liver disease (NAFLD), a metabolic
condition strictly linked to insulin resistance [94], exhibited decreased PLP levels [95]. Although
the mechanism that links PLP to hepatic lipid accumulation needs further studies, it has also raised
the possibility that vitamin B6 levels could impact NAFLD by impairing polyunsatured fatty acids
(PUFA) interconversion. It was shown that vitamin B6 deficiency can contribute to reduce plasma (n-3)
and (n-6) PUFA concentrations in healthy subjects [96].
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5. Vitamin B6 and Diabetes Complications
People with diabetes have an increased risk of developing several serious health problems;
persistent high blood glucose levels can damage heart, blood vessels, eyes, kidney, and nerves. A large
body of evidence sustains that oxidative stress, combined with a reduced antioxidant defense, plays
a crucial role in diabetic complications [97–99].
It is thought that one of the main causes of diabetic complication is the formation of AGEs [100].
In diabetes, AGE accumulation is caused by hyperglycemia, through a spontaneous chemical
transformation of amine-containing molecules. Reducing sugars bind covalently free amino groups of
proteins, lipids, and guanyl nucleotides in DNA (Maillard reaction) to form adducts (Amadori products),
including glyoxal, methylglyoxal, and 3-deoxyglucosone (3-DG). These dicarbonyl compounds, apart
from being generated in Maillard reactions, also derive from glucose autoxidation, the polyol pathway,
and lipid peroxidation reactions. Since they are highly reactive and potent, glycating agents can
generate more AGEs by reacting with proteins, in turn [98]. It was shown that AGE accumulation
causes inflammation and destroys the normal structure and function of blood vessels, leading to
vascular complications [101]. AGEs can also act by bonding to RAGEs (receptor for advanced glycation
end-products) in plasma membrane and this interaction triggers different signaling pathways involved
in apoptosis, inflammation, angiogenesis, and vasopermeability [102]. Furthermore, AGEs increase
the production of reactive oxygen species (ROS), which impact genome integrity [103,104]. The increase
in ROS production can, in turn, promote the production of more AGEs, thereby forming a vicious
circle [101].
Some studies associated low B6 levels to diabetic complications, such as neuropathy and
retinopathy, in T1D and T2D patients [29,105]. While others reported a significant reduction
in neuropathy, after vitamin B6 supplementation [106] and reduced progression of diabetic
nephropathy [107,108]. Horikawa and coworkers [109] found a high vitamin B6 intake associated with
a lower incidence of diabetic retinopathy, in a cohort of T2D Japanese patients. Similar results were
obtained in experimental studies. Protective effects of PM in streptozotocin-diabetic rats are described
in secondary complications including retinopathy [110] and nephropathy [111]. Accordingly, it was
reported that pyridoxine oral administration reduced kidney injury and dysfunction in fat and fructose
(HD)-fed mice [112].
It is thought that vitamin B6 impacts diabetic complications mostly by its role as an antioxidant
molecule. Muellenbach and coworker [113] demonstrated that the combined treatment of PM and
alpha lipoic acid (a powerful antioxidant molecule) resulted in a substantial reduction of the oxidative
stress biomarkers in obese Zucker rats. More recently Abdullah and coworkers [114] demonstrated that
PM supplementation in alloxan-induced diabetic rats caused a significant decrease in both oxidative
stress parameters and ROS production, and consequently reduced DNA damage.
Regarding the mechanism through which vitamin B6 counteracts AGE formation, it was proposed
that PLP might trap the 3-DG, one of the AGE pathway metabolites [107,115]. In vitro experiments
showed that incubation with PLP markedly decreased concentration of 3-DG in a dose-dependent
manner, whereas PL and PM were less reactive. Other studies demonstrated that PM can form stable
complexes with metal ions that catalyze the oxidative reactions associated with the advanced stages
of protein glycation cascade [116]. Moreover, a density-functional theory (DFT) study indicated that
PM might react with reactive carbonyl compounds, generated as byproducts of protein glycation,
thereby, counteracting further protein damage [117]. More recently, Ramis and collaborators [118] also
emphasized the importance of the antioxidant role of PM in neutralizing AGE formation.
Besides diabetes complications, there is evidence that AGEs can also contribute to diabetes onset.
It was shown that glycated insulin display reduced activity [119]. Moreover, it was also proposed
that AGEs can directly damage the pancreatic β-cells, based on the finding that aminoguanidine
(AG), an AGE inhibitor, was able to protect islet β-cell function. Other studies proposed that AGEs
might impair insulin secretion by inhibiting cytochrome-c oxidase and adenosine triphosphate (ATP)
production [120].
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6. Vitamin B6 and DNA Damage in Diabetes
It is widely accepted that oxidative stress is a major risk factor for onset and progression
of diabetes. Many of the common risk factors, including obesity and unhealthy eating habits,
contribute to produce an oxidative environment that might increase insulin resistance or impair glucose
tolerance. Hyperglycemia, in turn, contributes to progression and maintenance of an overall oxidative
environment [121]. Consequently, diabetes was associated with reduced levels of antioxidants, such as
GSH, vitamin C, and vitamin E [122], and to a low efficiency of DNA repair systems [123,124].
Evidence indicated that both T1D and T2D diabetic patients exhibit oxidative damage and DNA
strand breaks [125,126]. It was shown that tissues from diabetic rats and the urine of T1D and T2D
patients have increased levels of 8-Oxo-7,8-dihydro-2′-deoxyguanosine (8-oxodG), a sensitive marker
of reactive oxygen species (ROS)-induced DNA damage [127–129]. In addition, diabetic patients have
a higher frequency of sister chromatid exchange than healthy subjects [130,131]. Another study reported
high levels of stable chromosomal aberrations in peripheral lymphocytes associated with T2D, and
directly correlated with the risk of early diabetes-related death [131]. Moreover, an elevated frequency
of micronuclei was found in T2D patients with no microvascular or macrovascular complications [132].
Recently, micronuclei frequency was positively related to glycated hemoglobin (HbA1c) levels, as well
as to fasting plasma glucose in T2D [133].
By considering that PLP is both an antioxidant molecule and a cofactor for enzymes involved in
DNA metabolism, it is expected that its reduced availability can contribute to increase DNA damage
associated with diabetes. Studies in Drosophila and human cell cultures helped to gain evidence in
support of this hypothesis, demonstrating that PLP deficiency can cause DNA damage throughout
the formation of AGEs [45,46]. We demonstrated in fact that PLP deficiency in Drosophila and human
cultured cells, trigger the formation of chromosome aberrations (CABs). In particular, mutations in
the pyridoxal kinase gene (dPdxk1) as well as the RNAi-induced silencing of pyridoxine 5′-phosphate
oxidase gene (sgll), produced CABs in brain cells [45,46]. Similarly, CABs were produced in wild-type
individuals through PLP inhibitors, such as 4-DP, cycloserine, isoniazid, and penicillamine [45].
Interestingly, in all of these cases, CAB frequency was strongly enhanced by treatment with sugars,
such as glucose, fructose, or sucrose, whereas in contrast, sugar treatments did not induce CABs in
wild-type brains. In addition to providing the first evidence that correlates vitamin B6, DNA damage,
and hyperglycemia, these data [45,46] also indicate that low PLP levels and high glucose might
synergize in the process of CAB formation. Notably, PLP-depleted cells accumulated significant levels
of AGEs, whose formation is enhanced by glucose treatment [45,46]. Remarkably, the treatment with
the antioxidant alpha-lipoic acid, rescued not only AGEs but also CABs [45,46], further highlighting
the cause–effect relationship between high glucose and CABs in low PLP conditions. These data
allowed building a model, according to which decreased PLP levels induce hyperglycemia, which in
turn produces AGEs that are responsible for DNA damage through ROS formation. This model could
also be applied to humans, based on the following considerations—(1) the human PDXK gene inserted
in dPdxk1 mutant flies is capable of reducing hyperglycemia, CABs, and AGE accumulation [45]; (2)
RNAi-induced silencing of the human PDXK gene produces CABs in fibroblasts and HeLa cells, as well
as 4-DP treatment in mock cells [45]; (3) alpha-lipoic acid treatment rescued DNA damage induced
by PDXK depletion [45]; (4) the expression in the dPdxk1 mutant flies of 4 PDXK human variants
with reduced or impaired catalytic activity did not rescue CABs nor AGEs [53]. Taken together, these
data suggest not only that low PLP levels could contribute to produce DNA damage in diabetic cells
throughout AGE formation, but more importantly, that diabetic patients need to monitor their PLP
content to avoid DNA damage, which is a well-known cancer prerequisite.
7. Vitamin B6 Diabetes and Cancer
Diabetic patients have an increased risk for developing different types of tumors, including liver,
pancreas, colorectal, and lung cancers, but the underlying mechanisms are not fully elucidated [134–136].
Hyperinsulinemia and hyperglycemia were hypothesized to have a role in mediating this association,
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mainly by promoting cell growth [137]. However, it is thought that hyperglycemia might also impact
cancer by triggering DNA damage through AGEs and ROS formation.
Based on the above-mentioned findings obtained in Drosophila, by considering that DNA damage
caused by PLP deficiency is sugar-sensitive, it is reasonable to suppose that in a given diabetic context,
the combined action of reduced PLP availability and high endogenous glucose levels could increase
the severity of DNA damage. Evidence supporting this hypothesis was provided by studies in
Drosophila. It was demonstrated in fact that treatment with 4-DP resulted in much more severe DNA
damage in diabetic individuals than in wild-type flies [51]. In particular, brains from two different
fly models of T2D displayed 60–80% of CABs (vs. 25% in 4-DP treated wild-type individuals) and
accumulated many more AGEs. Additionally, treatment with alpha-lipoic acid rescued both AGEs
and CABs, confirming that CABs were largely produced by AGEs [51]. Consequently, extrapolated to
humans, this finding indicates that low PLP levels might contribute to increased cancer-risk in diabetic
patients. It is possible, in fact, to envisage that in an oxidative environment in which antioxidant
defenses and DNA repair are weakened, a decline in the capability to counteract AGEs and ROS
induced by low PLP levels, might cause an amplification of genotoxic effects, increasing the risk for
developing cancer.
8. Conclusions
In conclusion, compelling evidence demonstrates that vitamin B6 and diabetes are strictly
associated through multiple mechanisms and pathways. In T1D, vitamin B6 essentially protects from
complications, whereas the hypothesis that it might impact diabetes onset, by triggering autoimmunity,
requires further studies. In contrast, the impact of vitamin B6 on T2D is higher due to the different
pathophysiology of the two diseases. In T2D, the reduced vitamin B6 availability besides contributing
to development of complications can also promote diabetes onset. By examining the literature, it
appears that vitamin B6 deficiency can be both a consequence and cause of diabetes (Figure 3). In
the first scenario, in contexts including pregnancy and obesity, an increased demand of vitamin B6
from specific PLP-dependent enzymes, as well as the trigger of inflammation pathways, can reduce
its availability. In the second scenario, reduced vitamin B6 levels might trigger diabetes onset by
impacting the insulin secretion or its biological activity. In this case, mechanisms including enhanced
tryptophan catabolism through the kynurenine pathway, reduced rate of adipogenesis, impaired lipid
metabolism, or reduced capability to counteract AGE formation, might all contribute to promote
diabetes. Furthermore, an impaired antioxidant activity of vitamin B6 can also favor the development
of diabetes complications. By also considering the role played by PLP in chromosome integrity
maintenance and the high cancer-risk associated with diabetic pathology, it is important to perform
further studies to fully clarify molecular mechanisms that link vitamin B6 to diabetes and to confirm in
higher organisms the hypothesis that vitamin B6 might contribute to promoting cancer in diabetes.
This might allow us to find optimal protocols and strategies to ameliorate diabetes, as well as to
decrease cancer-risk in diabetic patients
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